Venus Remedies Limited has received Good Manufacturing Practices (GMP) approval with PIC/S accreditation from the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for its pre-filled syringe manufacturing facility in Baddi, India. The certification, announced on November 5, 2024, marks the company’s first PIC/S GMP accreditation for its PFS facility.
Shares of Venus Remedies Limited were trading at ₹311.60 at 10:30 am today, up ₹1.70 or 0.55 percent on the NSE.
The approval will allow Venus Remedies to expedite regulatory approvals in other PIC/S member states through mutual recognition agreements. The company’s robotic facility can produce more than 20 million units of enoxaparin, an anticoagulant drug used to prevent and treat blood clots, annually.
- Also read: Dr. Reddy’s is likely to post a decline in net profit in the second quarter of FY25
The certification process was completed within six months of an audit in April 2024. Venus Remedies currently holds marketing authorizations for enoxaparin in several markets including Saudi Arabia, Azerbaijan, the Philippines and Myanmar.
- Also read: Apollo Hospitals to invest ₹6,100 crore in adding 3,500 beds across 11 locations by FY26
The global enoxaparin market, estimated at USD 3,315 million in 2023, is expected to reach USD 5,415 million by 2030, with a CAGR of 7.1 percent. Headquartered in Panchkula, Venus Remedies operates in more than 80 countries and has nine manufacturing facilities worldwide, including locations in Panchkula, Baddi and Werne, Germany.
